New partnership delivers critical insights to more cardiovascular care teams to identify and define atherosclerosis earlier SAN FRANCISCO – September 4, 2024 — Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, and Cleerly, the company working to create a new standard of care for the diagnosis of heart […]
Author: Ken Dropiewski
Harrison.ai launches world leading AI model to transform healthcare
Harrison.rad.1 significantly outperforms other major models on radiology tasks The new model is being made accessible to select healthcare professionals and regulators to open up the conversation on responsible use of AI in healthcare SYDNEY, Sept. 4, 2024 /PRNewswire/ — Healthcare AI…
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors (“Board”), effective September 3, 2024.
AngioDynamics Announces CE Mark Approval in Europe for the Auryon System
September 03, 2024 08:30 AM Eastern Daylight Time LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced European CE Mark approval of the […]
Renata Medical Announces First Patient to Receive Minima Growth Stent Following FDA Approval
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Renata Medical, a leader in innovative vascular solutions for young, growing patients, proudly announces a major milestone with the successful implantation of its Minima Growth Stent in the first patient following its recent FDA approval. “Today marks the beginning of something special” Post this “Today marks the […]
ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor Meets Primary Endpoint and Clinical Results Confirm Unique Mechanism of Action
—Largest randomized data set to date on bioadaptor, with a complex patient population of 2,400 compared to a DES— —Primary endpoint of target lesion failure (TLF) non-inferiority at twelve months was met with a low event rate for DynamX despite increased patient complexity— —Pre-specified landmark analysis shows statistically significant reduction […]
ADLM publishes new guidance on lipid testing to improve care for patients with cardiovascular disease
WASHINGTON, Sept. 3, 2024 /PRNewswire/ — The Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) has issued expert guidance on lipid tests, which measure blood levels of fats and cholesterol to help assess a patient’s risk of heart disease and stroke. By giving…
Stereotaxis Robotic Technology to be Featured during Heart Rhythm Society’s HRX Congress
ST. LOUIS, Sept. 03, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its technology will be prominently featured during the upcoming HRX digital health conference taking place September 5-7, 2024, in Atlanta, Georgia.
Caristo Diagnostics Recognized as Quarterfinalist in the Digital Health Awards, Rising Star Category
OXFORD, England, Sept. 3, 2024 /PRNewswire/ — Caristo Diagnostics, a global leader in cardiovascular disease diagnostics and risk prediction, has been selected as a quarterfinalist for the prestigious Digital Health Hub Foundation: Digital Health Awards. Caristo was chosen as a…
Vasa Therapeutics Announces Initiation of Phase 1 First-in-Human Clinical Trial of VS-041 for the Treatment of Heart Failure with Preserved Ejection Fraction
Vasa Therapeutics granted MHRA Clinical Trial Authorization (CTA) for VS-041 for the treatment of heart failure with preserved ejection fraction (HFpEF) Company’s seed funding extended to $11M ENCINITAS, Calif. and WROCLAW, Poland, Sept. 3, 2024 /PRNewswire/ — Vasa Therapeutics (“Vasa”),…



